General Information
Version
8.0
Revision date
2023-08-30
Product name
Almotriptan for system suitability CRS
CAS No.
154323-57-6
REACH No
A
Emergency telephone
55 0800 707 7022, 55 0800 117 2020, 55 11 4349 1359
Icons in SDS
Company Information
company name
Sigma-Aldrich Brasil Ltda
e-mail address of the competent person responsible for the Safety Data Sheet
suporte-cientifico@merckgroup.com
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H373
Hazard statements
Code
Statements
H373
May cause damage to organs through prolonged or repeated exposure
Section 2
SECTION 2: Hazards identification
Regulation (EC) No. 1272/2008 Classification of the substance or mixture
Signal word
Warning Warning
Hazard statements
H373 May cause damage to organs through prolonged or repeated exposure. Reduced Labeling (<= 125 ml) none
Precautionary statements
P260 Do not breathe dust. P314 Get medical advice/ attention if you feel unwell. P501 Dispose of contents/ container to an approved waste disposal plant. none
Supplemental label elements
none none
2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
ECOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
TOXICOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
2.1 Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 Specific target organ toxicity - repeated exposure (Category 2), H373 For the full text of the H-Statements mentioned in this Section, see Section 16.
